New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
10:01 EDTIVZ, HP, VIA, MW, HES, EA, VIAB, EPD, KKD, WHR, TWC, MA, HBC, ALKS, RDS.A, LTM, STZ, ARR, UPS, ZQK, HOLX, BOBE, BUDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AB InBev (BUD) downgraded to Hold from Buy at Societe Generale... ARMOUR Residential (ARR) downgraded to Neutral from Buy at BofA/Merrill... Alkermes (ALKS) downgraded to Neutral from Buy at BofA/Merrill... Bob Evans (BOBE) downgraded to Hold from Buy at KeyBanc... Constellation Brands (STZ) downgraded to Neutral from Buy at BofA/Merrill... HSBC (HBC) downgraded to Neutral from Buy at Citigroup... Hologic (HOLX) downgraded to Reduce from Neutral at SunTrust... Life Time Fitness (LTM) downgraded to Market Perform from Outperform at William Blair... MasterCard (MA) downgraded to Market Perform from Outperform at Wells Fargo... Quiksilver (ZQK) downgraded to Neutral from Outperform at RW Baird... Royal Dutch Shell (RDS.A) downgraded to Underperform from Neutral at BofA/Merrill... Time Warner Cable (TWC) downgraded to Hold from Buy at Deutsche Bank... UPS (UPS) downgraded to Neutral from Buy at Citigroup... Viacom (VIAB) downgraded to Neutral from Overweight at Piper Jaffray... Whirlpool (WHR) downgraded to Outperform from Strong Buy at Raymond James... Electronic Arts (EA) downgraded to Neutral from Long-Term Buy at Hilliard Lyons... Helmerich & Payne (HP) downgraded to Neutral from Add at Capital One... Time Warner Cable (TWC) downgraded to Neutral from Buy at Guggenheim... Krispy Kreme (KKD) downgraded to Neutral from Buy at B. Riley Caris... Hess Corp. (HES) downgraded to Accumulate from Buy at Global Hunter... Invesco (IVZ) downgraded to Equal Weight from Overweight at Morgan Stanley... Enterprise Products (EPD) downgraded to Neutral from Outperform at Credit Suisse... Men's Wearhouse (MW) downgraded to Neutral from Outperform at Cowen.
News For A;TWC;UPS;VIAB;VIA;WHR;EA;HP;KKD;HES;IVZ;EPD;MW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 18, 2015
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:26 EDTEPDEnterprise Products initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:50 EDTKKDKrispy Kreme signs development agreement to open 31 shops in South Africa
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
14:01 EDTWHRWhirlpool enters agreement to acquire American Dryer Corporation
Subscribe for More Information
10:01 EDTHESOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:27 EDTVIAJPMorgan to hold a conference
Subscribe for More Information
06:44 EDTHESHess Corp. downgraded to Neutral from Buy at Goldman
Goldman downgraded Hess to Neutral and lowered its price target to $68 from $80 based on reduced upside from lower oil/gas price forecasts.
May 17, 2015
18:31 EDTTWCBanks prepare $25B funding in case of Charter-Time Warner deal, Reuters says
Subscribe for More Information
May 15, 2015
16:32 EDTVIABBerkshire Hathaway gives quarterly update on stakes
NEW STAKES: None. INCREASED STAKES: IBM (IBM), Precision Castparts (PCP), Wells Fargo (WFC), Phillips 66 (PSX), and US Bancorp (USB). DECREASED STAKES: National Oilwell Varco (NOV), Viacom (VIAB), Bank of New York Mellon (BK), MasterCard (MA), and Visa (V). LIQUIDATED STAKES: None.
16:28 EDTWHRAppaloosa Management gives quarterly update on stakes
Subscribe for More Information
10:01 EDTUPSOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aspen Technology (AZPN) upgraded to Overweight from Sector Weight at Pacific Crest... Canadian National (CNI) upgraded to Outperform from Sector Perform at Scotia Capital... Connecticut Water (CTWS) upgraded to Outperform from Market Perform at Wells Fargo... Hanesbrands (HBI) upgraded to Buy from Neutral at DA Davidson... Impala Platinum (IMPUY) upgraded to Buy from Neutral at Goldman... Inovalon (INOV) upgraded to Buy from Neutral at Goldman... J.C. Penney (JCP) upgraded to Market Perform at BMO Capital... Sovran Self Storage (SSS) upgraded to Buy from Neutral at UBS... Syngenta (SYT) upgraded to Neutral from Underperform at Exane BNP Paribas... UPS (UPS) upgraded to Buy from Neutral at Goldman... Union Pacific (UNP) upgraded to Buy from Hold at TD Securities... Yum! Brands (YUM) upgraded to Overweight from Neutral at JPMorgan.
09:03 EDTWHRBofA/Merrill says to buy Home Depot, Lowe's and Whirlpool
Subscribe for More Information
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
07:09 EDTHPHayman Capital gives quarterly update on stakes
Subscribe for More Information
05:52 EDTEAApril NPD video game software sales rose 13%, says Piper Jaffray
Piper Jaffray notes April NPD video game software sales increased 13% year-over-year with next-generation software revenue up 200% versus the prior year. Piper keeps Overweight ratings on Activision Blizzard (ATVI), Electronic Arts (EA), GameStop (GME) and Take-Two (TTWO).
05:46 EDTUPSUPS upgraded to Buy from Neutral at Goldman
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use